Literature DB >> 18753255

FGFR3 and FGFR4 do not mediate renal effects of FGF23.

Shiguang Liu1, Luke Vierthaler, Wen Tang, Jianping Zhou, L Darryl Quarles.   

Abstract

Fibroblast growth factor 23 (FGF23) is a phosphaturic factor that suppresses both sodium-dependent phosphate transport and production of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] in the proximal tubule. In vitro studies suggest that FGFR3 is the physiologically relevant receptor for FGF23 in the kidney, but this has not been established in vivo. Here, immunohistochemical analysis of the mouse kidney revealed that the proximal tubule expresses FGF receptor 3 (FGFR3) but not FGFR1, FGFR2, or FGFR4. Compared with wild-type mice, Hyp mice, which have elevated circulating levels of FGF23, exhibited low levels of serum phosphate and 1,25(OH)(2)D, reduced expression of the sodium-dependent phosphate transporter NPT2a in the proximal tubules, and low bone mineral density as a result of osteomalacia. In contrast, neither the serum phosphate nor 1,25(OH)(2)D levels were altered in FGFR3-null mice. For examination of the role of FGFR3 in mediating the effects of FGF23, Hyp mice were crossed with FGFR3-null mice; interestingly, this failed to correct the aforementioned metabolic abnormalities of Hyp mice. Ablation of FGFR4 also failed to correct hypophosphatemia in Hyp mice. Because the ablation of neither FGFR3 nor FGFR4 inhibited the renal effects of excess FGF23, the kidney localization of FGFR1 was investigated. FGFR1 co-localized with Klotho, the co-factor required for FGF23-dependent FGFR activation, in the distal tubule. In summary, neither FGFR3 nor FGFR4 is the principal mediator of FGF23 effects in the proximal tubule, and co-localization of FGFR1 and Klotho suggests that the distal tubule may be an effector site of FGF23.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753255      PMCID: PMC2588103          DOI: 10.1681/ASN.2007121301

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  41 in total

1.  Fibroblast growth factor receptors and their ligands in the adult rat kidney.

Authors:  B Cancilla; A Davies; J A Cauchi; G P Risbridger; J F Bertram
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

2.  Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys.

Authors:  Y Kato; E Arakawa; S Kinoshita; A Shirai; A Furuya; K Yamano; K Nakamura; A Iida; H Anazawa; N Koh; A Iwano; A Imura; T Fujimori; M Kuro-o; N Hanai; K Takeshige; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  2000-01-19       Impact factor: 3.575

3.  Intranephron PGE2 production in stroke-prone spontaneously hypertensive rats.

Authors:  F Takemoto; A Miyanoshita; K Shimamura; S Sunano; H Endou
Journal:  Am J Physiol       Date:  1990-04

4.  FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.

Authors:  A E Bowe; R Finnegan; S M Jan de Beur; J Cho; M A Levine; R Kumar; S C Schiavi
Journal:  Biochem Biophys Res Commun       Date:  2001-06-22       Impact factor: 3.575

5.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Authors:  T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

8.  Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro.

Authors:  Hua Wang; Yuji Yoshiko; Ryoko Yamamoto; Tomoko Minamizaki; Katsuyuki Kozai; Kazuo Tanne; Jane E Aubin; Norihiko Maeda
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

9.  fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation.

Authors:  T P Yamaguchi; K Harpal; M Henkemeyer; J Rossant
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

10.  Murine FGFR-1 is required for early postimplantation growth and axial organization.

Authors:  C X Deng; A Wynshaw-Boris; M M Shen; C Daugherty; D M Ornitz; P Leder
Journal:  Genes Dev       Date:  1994-12-15       Impact factor: 11.361

View more
  54 in total

1.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

2.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 3.  Regulation of Long Bone Growth in Vertebrates; It Is Time to Catch Up.

Authors:  Alberto Roselló-Díez; Alexandra L Joyner
Journal:  Endocr Rev       Date:  2015-10-20       Impact factor: 19.871

4.  Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport.

Authors:  W Bruce Sneddon; Giovanni W Ruiz; Luciana I Gallo; Kunhong Xiao; Qiangmin Zhang; Youssef Rbaibi; Ora A Weisz; Gerard L Apodaca; Peter A Friedman
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 5.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 6.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

7.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

8.  Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.

Authors:  Guoying Liang; Lee D Katz; Karl L Insogna; Thomas O Carpenter; Carolyn M Macica
Journal:  Calcif Tissue Int       Date:  2009-07-17       Impact factor: 4.333

Review 9.  Post-renal transplantation hypophosphatemia.

Authors:  Khashayar Sakhaee
Journal:  Pediatr Nephrol       Date:  2009-07-15       Impact factor: 3.714

10.  FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.

Authors:  Jyothsna Gattineni; Carlton Bates; Katherine Twombley; Vangipuram Dwarakanath; Michael L Robinson; Regina Goetz; Moosa Mohammadi; Michel Baum
Journal:  Am J Physiol Renal Physiol       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.